One study showed that high pre-NAC TIL levels were clearly predictive of pCR and can act as a surrogate marker to predict therapeutic effects of a dual-targeted neoadjuvant treatment regimen for HER2-amplified breast cancer (41). This evidence concerns the gene ERBB2 and breast cancer.